vs
Side-by-side financial comparison of GAXOS.AI INC. (GXAI) and Instil Bio, Inc. (TIL). Click either name above to swap in a different company.
Instil Bio, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.2M, roughly 1.8× GAXOS.AI INC.). GAXOS.AI INC. runs the higher net margin — -77.2% vs -365.3%, a 288.1% gap on every dollar of revenue. On growth, GAXOS.AI INC. posted the faster year-over-year revenue change (94996.3% vs -19.2%).
Instil Bio Inc. is a clinical-stage biotechnology company focused on developing innovative tumor-infiltrating lymphocyte (TIL) therapies for patients with difficult-to-treat advanced solid tumors. It operates in the immuno-oncology segment, serving patient populations that show limited response to existing standard cancer treatment options.
GXAI vs TIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $2.2M |
| Net Profit | $-957.9K | $-8.2M |
| Gross Margin | — | — |
| Operating Margin | -99.0% | -426.3% |
| Net Margin | -77.2% | -365.3% |
| Revenue YoY | 94996.3% | -19.2% |
| Net Profit YoY | -15.1% | 31.1% |
| EPS (diluted) | $-0.13 | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $2.2M | ||
| Q3 25 | $498.3K | $2.2M | ||
| Q2 25 | $171.0K | $2.2M | ||
| Q1 25 | — | $2.2M | ||
| Q4 24 | — | $2.8M | ||
| Q3 24 | — | $1.5M | ||
| Q2 24 | $0 | $0 | ||
| Q1 24 | — | $0 |
| Q4 25 | $-957.9K | $-8.2M | ||
| Q3 25 | $-1.0M | $-13.6M | ||
| Q2 25 | $-749.4K | $-21.4M | ||
| Q1 25 | — | $-28.2M | ||
| Q4 24 | — | $-11.9M | ||
| Q3 24 | — | $-23.0M | ||
| Q2 24 | $-809.2K | $-14.9M | ||
| Q1 24 | — | $-24.3M |
| Q4 25 | -99.0% | -426.3% | ||
| Q3 25 | -263.9% | -670.0% | ||
| Q2 25 | -574.8% | -1045.5% | ||
| Q1 25 | — | -1363.2% | ||
| Q4 24 | — | -426.1% | ||
| Q3 24 | — | -1582.8% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -77.2% | -365.3% | ||
| Q3 25 | -201.0% | -606.0% | ||
| Q2 25 | -438.3% | -954.2% | ||
| Q1 25 | — | -1257.8% | ||
| Q4 24 | — | -428.8% | ||
| Q3 24 | — | -1541.9% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-0.13 | $-1.13 | ||
| Q3 25 | $-0.14 | $-2.01 | ||
| Q2 25 | $-0.11 | $-3.24 | ||
| Q1 25 | — | $-4.32 | ||
| Q4 24 | — | $-1.82 | ||
| Q3 24 | — | $-3.54 | ||
| Q2 24 | $-0.72 | $-2.29 | ||
| Q1 24 | — | $-3.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $840.5K | $6.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $13.1M | $113.9M |
| Total Assets | $13.4M | $203.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $840.5K | $6.6M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | — | $7.7M | ||
| Q1 25 | — | $15.4M | ||
| Q4 24 | — | $8.8M | ||
| Q3 24 | — | $6.7M | ||
| Q2 24 | $4.5M | $6.8M | ||
| Q1 24 | — | $5.5M |
| Q4 25 | $13.1M | $113.9M | ||
| Q3 25 | $14.1M | $120.4M | ||
| Q2 25 | $15.0M | $131.7M | ||
| Q1 25 | — | $144.9M | ||
| Q4 24 | — | $169.4M | ||
| Q3 24 | — | $176.3M | ||
| Q2 24 | $4.7M | $195.0M | ||
| Q1 24 | — | $205.8M |
| Q4 25 | $13.4M | $203.5M | ||
| Q3 25 | $14.3M | $211.8M | ||
| Q2 25 | $15.4M | $231.0M | ||
| Q1 25 | — | $237.4M | ||
| Q4 24 | — | $263.6M | ||
| Q3 24 | — | $272.6M | ||
| Q2 24 | $5.1M | $294.3M | ||
| Q1 24 | — | $306.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-733.1K | $-7.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-733.1K | $-7.1M | ||
| Q3 25 | $-1.1M | $-10.6M | ||
| Q2 25 | $-716.9K | $-14.8M | ||
| Q1 25 | — | $-4.2M | ||
| Q4 24 | — | $-10.6M | ||
| Q3 24 | — | $-20.1M | ||
| Q2 24 | $-738.5K | $-10.6M | ||
| Q1 24 | — | $-14.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
